Cargando…

Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia

OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method for the treatment of refractory and relapsed acute leukemia, and the preconditioning methods before transplantationis one of the important factors affecting the survival of patients. Radiotherapy combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Fanyang, Liu, Shuaipeng, Liu, Lele, Pi, Yifei, Pei, Yuntong, Xu, Dandan, Jia, Fei, Han, Bin, Guo, Yuexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425557/
https://www.ncbi.nlm.nih.gov/pubmed/36052229
http://dx.doi.org/10.3389/fonc.2022.936985
_version_ 1784778475588026368
author Kong, Fanyang
Liu, Shuaipeng
Liu, Lele
Pi, Yifei
Pei, Yuntong
Xu, Dandan
Jia, Fei
Han, Bin
Guo, Yuexin
author_facet Kong, Fanyang
Liu, Shuaipeng
Liu, Lele
Pi, Yifei
Pei, Yuntong
Xu, Dandan
Jia, Fei
Han, Bin
Guo, Yuexin
author_sort Kong, Fanyang
collection PubMed
description OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method for the treatment of refractory and relapsed acute leukemia, and the preconditioning methods before transplantationis one of the important factors affecting the survival of patients. Radiotherapy combined with chemotherapy is the most commonly used preconditioning method before transplantation. This study evaluated the safety and efficacy of total bone marrow combined with total lymphatic irradiation as a preconditioning method before hematopoietic stem cell transplantation. METHODS: Seventeen patients with acute leukemia who were admitted to our center from 2016 to 2020 were selected. The median age was 17 years (8-35). The target area for TMLI includes the total bone marrow and total lymphatic space, and the organs at risk include the lens, lungs, kidneys, intestine, heart, and liver. The patients received a total bone marrow and lymphatic irradiation preconditioning regimen, the related acute adverse reactions were graded, and the prognosis of the patients after transplantation was observed. RESULTS: During patient preconditioning, only grade 1-2 toxicity was observed, and grade 3-4 toxicity did not occur. Except for one patient whose platelets were not engrafted, all the other patients were successfully transplanted. The median time of neutrophil implantation was 14 d (9-15 d), and the median time of platelet implantation was 14 d (13-21 d). With a median follow-up of 9 months (2-48), 4 relapses occurred, 3 died, and 10 leukemia patients survived and were disease-free. One-year overall survival was 69.8%, cumulative recurrence was 19.5%, disease-free-survival was 54.2%. CONCLUSION: The Allo-HSCT pretreatment regimen of total bone marrow combined with total lymphatic irradiation is safe and effective in the treatment of malignant hematological diseases. Total bone marrow combined with total lymphatic irradiation may completely replace total body irradiation, and the clinically observed incidence of acute toxicity is not high.
format Online
Article
Text
id pubmed-9425557
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94255572022-08-31 Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia Kong, Fanyang Liu, Shuaipeng Liu, Lele Pi, Yifei Pei, Yuntong Xu, Dandan Jia, Fei Han, Bin Guo, Yuexin Front Oncol Oncology OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method for the treatment of refractory and relapsed acute leukemia, and the preconditioning methods before transplantationis one of the important factors affecting the survival of patients. Radiotherapy combined with chemotherapy is the most commonly used preconditioning method before transplantation. This study evaluated the safety and efficacy of total bone marrow combined with total lymphatic irradiation as a preconditioning method before hematopoietic stem cell transplantation. METHODS: Seventeen patients with acute leukemia who were admitted to our center from 2016 to 2020 were selected. The median age was 17 years (8-35). The target area for TMLI includes the total bone marrow and total lymphatic space, and the organs at risk include the lens, lungs, kidneys, intestine, heart, and liver. The patients received a total bone marrow and lymphatic irradiation preconditioning regimen, the related acute adverse reactions were graded, and the prognosis of the patients after transplantation was observed. RESULTS: During patient preconditioning, only grade 1-2 toxicity was observed, and grade 3-4 toxicity did not occur. Except for one patient whose platelets were not engrafted, all the other patients were successfully transplanted. The median time of neutrophil implantation was 14 d (9-15 d), and the median time of platelet implantation was 14 d (13-21 d). With a median follow-up of 9 months (2-48), 4 relapses occurred, 3 died, and 10 leukemia patients survived and were disease-free. One-year overall survival was 69.8%, cumulative recurrence was 19.5%, disease-free-survival was 54.2%. CONCLUSION: The Allo-HSCT pretreatment regimen of total bone marrow combined with total lymphatic irradiation is safe and effective in the treatment of malignant hematological diseases. Total bone marrow combined with total lymphatic irradiation may completely replace total body irradiation, and the clinically observed incidence of acute toxicity is not high. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9425557/ /pubmed/36052229 http://dx.doi.org/10.3389/fonc.2022.936985 Text en Copyright © 2022 Kong, Liu, Liu, Pi, Pei, Xu, Jia, Han and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kong, Fanyang
Liu, Shuaipeng
Liu, Lele
Pi, Yifei
Pei, Yuntong
Xu, Dandan
Jia, Fei
Han, Bin
Guo, Yuexin
Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia
title Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia
title_full Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia
title_fullStr Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia
title_full_unstemmed Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia
title_short Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia
title_sort clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425557/
https://www.ncbi.nlm.nih.gov/pubmed/36052229
http://dx.doi.org/10.3389/fonc.2022.936985
work_keys_str_mv AT kongfanyang clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT liushuaipeng clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT liulele clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT piyifei clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT peiyuntong clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT xudandan clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT jiafei clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT hanbin clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia
AT guoyuexin clinicalstudyoftotalbonemarrowcombinedwithtotallymphaticirradiationpretreatmentbasedontomotherapyinhematopoieticstemcelltransplantationofacuteleukemia